Details for New Drug Application (NDA): 022244
✉ Email this page to a colleague
The generic ingredient in LUSEDRA is fospropofol disodium. Additional details are available on the fospropofol disodium profile page.
Summary for 022244
Tradename: | LUSEDRA |
Applicant: | Eisai Inc |
Ingredient: | fospropofol disodium |
Patents: | 1 |
DrugPatentWatch® Estimated Generic Entry Opportunity Date for 022244
Generic Entry Date for 022244*:
Constraining patent/regulatory exclusivity:
Dosage:
SOLUTION;INTRAVENOUS |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Profile for product number 001
Active Rx/OTC/Discontinued: | DISCN | Dosage: | SOLUTION;INTRAVENOUS | Strength | 1050MG/30ML (35MG/ML) | ||||
Approval Date: | Dec 12, 2008 | TE: | RLD: | No | |||||
Patent: | See Plans and Pricing | Patent Expiration: | Jul 1, 2022 | Product Flag? | Y | Substance Flag? | Y | Delist Request? | |
Patented Use: | SEDATIVE-HYPNOTIC AGENT INDICATED FOR MONITORED ANESTHESIA CARE (MAC) SEDATION |
Expired US Patents for NDA 022244
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Eisai Inc | LUSEDRA | fospropofol disodium | SOLUTION;INTRAVENOUS | 022244-001 | Dec 12, 2008 | See Plans and Pricing | See Plans and Pricing |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Complete Access Available with Subscription